On Tuesday, Mizuho Securities adjusted its outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $251 from the previous $277 while keeping an Outperform rating on the stock. The adjustment reflects a more conservative sales projection for Biogen's product acoramidis compared to the launch performance of a similar drug by Pfizer (NYSE:PFE).
The firm's analysis suggests a less aggressive sales trajectory for acoramidis, contrasting with the actual launch curve of Pfizer's tafamidis. Despite the price target revision, the analyst believes there are several key events ahead for Biogen that could influence the stock's performance.
These include the presentation of detailed results from Alnylam's HELIOS-B study at the European Society of Cardiology Congress, scheduled for August 30, 2024. The presentation is expected to include data on the primary endpoint and secondary endpoint of all-cause mortality, as well as subgroup analyses.
Moreover, updates on Biogen's BBP-631 program are anticipated in August, potentially including Phase 1/2 Cohort 4 data. Another significant date for the company is November 29, when the Prescription Drug User Fee Act (PDUFA) action date for acoramidis is set to occur. These events represent potential catalysts that could impact the company's stock in the coming months.
The revised price target and maintained rating reflect a balance between the tempered sales expectations for acoramidis and the upcoming milestones that could drive investor interest in Biogen. The firm's stance indicates a continued belief in the stock's potential despite the adjusted sales forecast.
In other recent news, Biogen has reported strong second-quarter results, with total revenue reaching $2.5 billion and a 5% increase in core pharmaceutical revenue. The company's non-GAAP diluted EPS grew by 31%, and it raised its full-year non-GAAP diluted EPS guidance to a range of $15.75 to $16.25. RBC Capital Markets has responded to these results by raising its price target for Biogen from $282 to $292, while maintaining an Outperform rating.
In contrast, Truist Securities has reduced its price target for Biogen to $302 from $340, despite retaining a Buy rating on the stock. These changes in analyst outlooks are part of recent developments surrounding the company. Truist's adjustment comes after the Committee for Medicinal Products for Human Use's opinion in the EU, which has affected Biogen's hopeful therapy, Leqembi.
On the other hand, RBC's upgrade follows Biogen's successful launches of Leqembi, Skyclarys, and Zurzuvae, alongside the acquisition of HI-Bio, which is expected to strengthen Biogen's position in the immunology market. Despite these contrasting views, both firms agree on Biogen's effective strategic execution and potential for future growth.
InvestingPro Insights
Biogen (BIIB) has been navigating a challenging market landscape, with recent data from InvestingPro highlighting a mix of cautionary and promising signals for investors. As Mizuho Securities revises its price target for Biogen, the company's stock exhibits characteristics that warrant a closer look.
With a market capitalization of $28.9 billion and a price-to-earnings (P/E) ratio standing at 24.8, Biogen is a substantial player in the biotechnology industry. The adjusted P/E ratio over the last twelve months as of Q2 2024 is more favorable at 16.51, suggesting a potentially undervalued stock in comparison to earnings.
InvestingPro Tips indicate that Biogen's stock is currently in oversold territory according to the RSI, and analysts have revised their earnings expectations downwards for the upcoming period. Despite this, the company is expected to remain profitable this year.
Biogen's low price volatility and its tendency to move counter to market trends could provide a degree of stability for investors. Moreover, the company's liquid assets surpass short-term obligations, which is a reassuring sign of financial health.
From a performance standpoint, Biogen's revenue for the last twelve months as of Q2 2024 stands at $9.672 billion, with a gross profit margin of 76.92%, reflecting strong profitability in its operations. However, revenue growth has experienced a slight decline of 3.0%. With key events on the horizon, such as the HELIOS-B study results and the PDUFA action date for acoramidis, these financial metrics and the InvestingPro Tips can help investors gauge the potential risks and rewards associated with Biogen's stock.
InvestingPro offers additional insights and tips for Biogen, which can provide investors with a more comprehensive understanding of the stock's potential. These include the stock's current trading near its 52-week low and the prediction of its profitability this year. For those seeking further guidance, there are 18 more InvestingPro Tips available for Biogen at https://www.investing.com/pro/BIIB.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.